NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $898M | $783M | $595M | $390M | $339M | $257M | $229M | $147M | $101M | −$94M | −$106M | −$38M | −$47M | −$30M | −$35M | −$698K | $50M | −$53M |
| Capital expenditures | — | $34M | $38M | $28M | $17M | $23M | $11M | $15M | $25M | $6.9M | $4.1M | $1.9M | $1.6M | $545K | $971K | $750K | $315K | $35K |
| Free cash flow | — | $749M | $557M | $362M | $323M | $233M | $218M | $132M | $77M | −$101M | −$110M | −$40M | −$49M | −$30M | −$36M | −$1.4M | $50M | −$53M |
| Stock-based compensation | $235M | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | $6.8M | $5.5M | $2.9M | $3.1M | $5.5M |
| Buybacks | $66M | $168M | $300M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | — | 26.2% | 23.7% | 19.2% | 21.7% | 20.6% | 20.8% | 16.8% | 17.0% | −62.7% | −735.3% | −202.0% | — | −1,033.0% | −68.2% | −1.9% | 148.1% | −1,799.2% |